Idorsia Ltd (LON:0RQE)

Market Cap	141.77M
Revenue (ttm)	99.17M
Net Income (ttm)	-232.39M
Shares Out	n/a
EPS (ttm)	-1.28
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,657
Average Volume	13,136
Open	11.76
Previous Close	12.25
Day's Range	11.40 - 11.76
52-Week Range	2.87 - 17.80
Beta	1.22
RSI	55.80
Earnings Date	Feb 27, 2025

About Idorsia

Idorsia Ltd, a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for unmet medical needs in Switzerland. The company has a clinical development pipeline that cover various therapeutic areas, including CNS, cardiovascular, and immunological disorders, as well as orphan diseases. Its products include PIVLAZ (clazosentan), available in 150 mg, is indicated for the prevention of cerebral vasospasm, vasospasm-related cerebral infarction, and cerebral ischemic symptoms after aneurysmal subarachnoid hemor...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2017
• Employees: 650
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0RQE

Financial Performance

In 2024, Idorsia's revenue was 112.51 million, a decrease of -26.17% compared to the previous year's 152.39 million. Losses were -263.64 million, -11.51% less than in 2023.

Financial numbers in CHF